Effect of Bevacizumab on Human Corneal Endothelial Cell: A ix-month Follow-up tudy Original Reearch Article

Purpoe To ae in vivo corneal endothelial change occurring over a ix-month period after the intravitreal injection of bevacizumab (Avatin; Genentech Inc, an Francico, California, UA) in patient with variou macular dieae. Deign Propective cae erie. Method A total of 50 eye from 50 conecutive patient received an intravitreal injection of 2.5 mg intravitreal bevacizumab. pecular microcopy, including central corneal thickne (CCT) and endothelial cell count, wa performed on each patient for both eye before injection and one day, even day, three month, and ix month after injection. The CCT at one and even day wa meaured to evaluate the acute corneal endothelial damage; endothelial cell count at three and ix month wa ued to etimate chronic corneal endothelial change. Reult All patient completed ix month of follow-up. There wa no ignificant difference in corneal thickne change between treated and nontreated eye before injection or one and even day after injection (P = .53, .34, and .87, repectively). There wa alo no difference in the treated eye before injection and one and even day after injection (P = .94). Long-term evaluation revealed that there wa no ignificant difference in the corneal endothelial cell denity of treated and nontreated eye before injection and at three and ix month after injection (P = .76, .13, and .22, repectively). There wa alo no difference in the treated eye before injection and at three and ix month after injection (P = .73). Concluion The intravitreal injection of 2.5 mg bevacizumab eemed to have no harmful effect on the corneal endothelium.